An analysis of patients with HIV who were being treated for hepatitis C virus infection found that 7% failed direct-acting antiviral therapy, and that mental illness and ongoing illicit drug use often predicted failure, researchers reported.
“Real-world studies have confirmed the high efficacy and excellent tolerability of direct-acting antivirals (DAA) for the treatment of hepatitis C virus (HCV) infection in people living with HIV (PLWH). Overall, more than 90% of PLWH treated with DAAachieve cure. Hence, the World Health Organization proposed goals to eliminate HCV by 2030, and the British HIV Association considered that HCV could be eliminated in PLWH in the United Kingdom by 2021,” Edward R. Cachay, MD,professor of clinical medicine at the University of California, San Diego, and colleagues wrote in Open Forum Infectious Diseases.
“To achieve this goal, we need to decrease the proportion of PLWH with ongoing HCV viremia through HCV screening, linkage, treatment uptake and implementation of harm reduction strategies to prevent HCV re-infection. The causes of HCV treatment failure and resulting ongoing HCV viremia are different depending on whether there is virologic failure or premature treatment discontinuation.”